Norway· NO-ID_A3722DAE-078C-48FC-8EA2-F6F53803B4F8
Briumvi
A ublituximab product containing ublituximab, registered in Norway by Neuraxpharm Pharmaceuticals, S.L.. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ublituximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Ublituximab · ATC L04AG14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Ublituximab
- Manufacturer
- Neuraxpharm Pharmaceuticals, S.L.
- Country
- Norway (NO)
- ATC code
- L04AG14
- ATC class
- Ublituximab
- Defined daily dose
- 2.68 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_A3722DAE-078C-48FC-8EA2-F6F53803B4F8
- no_varenummer0522651 x 6NOK 50324.1
- gtin8436027473275
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- BelgiumBriumvi 150 mgNeuraxpharm Pharmaceuticals
- FinlandBriumviNeuraxpharm Pharmaceuticals S.L.
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- IcelandBriumviNeuraxpharm Pharmaceuticals S.L.
- SwedenBriumvi 150 mg Koncentrat till infusionsvätska, lösningNeuraxpharm Pharmaceuticals S.L.
- SwitzerlandBriumvi
- United KingdomBriumvi 150mg/6ml concentrate for solution for infusion vialsNeuraxpharm UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Briumvi
- Liechtenstein · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7eabf2f-7c00-43ab-b27a-aaeeea034759 GET /v1/drugs/b7eabf2f-7c00-43ab-b27a-aaeeea034759?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Ublituksimab",
"merkevare_id": "ID_A3722DAE-078C-48FC-8EA2-F6F53803B4F8",
"name_form_strength": "Briumvi kons til inf oppl 150 mg",
"prescription_group": "C"
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.